Preliminary programme COPD8
Preliminary Programme COPD8
20-22 June 2012
PS1.




The 21st century health care challenge of chronic non-communicable diseases
Extent of global problem
Challenge for healthcare systems - USA
- Europe
Value based healthcare
How do we interrupt the Tsunami?
Round table discussion
PS2.





COPD and Co-morbidity
Co-morbidity, which diseases?
The heart and the lung, how they are linked
COPD and Lung Cancer
COPD and IPF: common start, different end point
Round table discussion
PS3.

Challenges of COPD diagnosis and management in primary care
Making the diagnosis
- Fixed ratio
- Lower Limit of Normal
- Good spirometric standards
Improving the quality of care (what are the challenges)
Integrated and shared care aims/targets
It is not just managing FEV1



Bart Celli (USA)
Bill MacNee (UK)
Javier Zulueta (Spain)
George Washko (USA)
PS4. ‘Infection’ and COPD – an update

Infective phenotypes – do they exist?
Marc Miravitlles (Spain)

Do colds influence the nature of exacerbations?
Sebastian Johnston (UK)

Should we characterise exacerbations?
- Pro
Wisia Wedzicha (UK)
- Con
Rob Stockley (UK)

Can we identify early and should we intervene despite patients view? Shawn Aaron (Can)
PS5. Can COPD treatment be personalised: Triumphs and disappointments

Patient expectations
Helena Shovelton (UK) & John Walsh (USA)

Achieving personalised treatment of COPD based on ( short presentations )
- clinical phenotype & genotype (COPD gene)
James Crapo (USA)
- phenotypes & biomarkers
David Lomas (UK)
- using the GOLD approach
Jorgen Vestbo (Den)
- overlap syndrome
Chris Brightling (UK)

Debate: This house thinks it is a waste of time
Preliminary programme COPD8
Basic Science Mini Symposia
BS1. Neutrophil Migration
This session reconsiders the potential role of the neutrophil in the pathophysiology of COPD
exploring recent knowledge of cell function
Chair: Edwin Chilvers & Liz Sapey

Introduction: The traditional role of the neutrophil

Neutrophil transit

Neutrophil migration

Neutrophil NETs

Neutrophil and tissue damage

Panel discussion
Rob Stockley (UK)
Edwin Chilvers (UK)
tbc
tbc
Alison Condliffe (UK)
BS2. The COPD Scientific year in perspective (1)
Technological advances has led to information overload in the study of ‘omics’. This session
provides a realistic update of these advances
Chair:






Professor Gary Anderson & Professor David Lomas
Introduction: How do we handle information overload
Microbiome
Fernando Martinez (USA)
Proteomics
tbc
Biomarkers
Bart Celli (USA)
Immunology
Guy Brusselle (Bel)
Panel discussion
Gary Anderson (Aus)
BS3. COPD models
This session describes new models being used to explore the pathophysiology of COPD
Chair:







Moira Whyte (UK)
Introduction: What contributes an ideal model / models
Skin models
Ian Sabroe (UK)
Endotoxin challenge
Dave Singh (UK)
Explanted lung
Paul Corris (UK)
Bio-artificial lung
Matthew Hind (UK)
Zebra fish
Steve Renshaw (UK)
Panel discussion
BS4. The COPD Scientific year in perspective (2)
Moira Whyte (UK)
This provides an update on the understanding of mechanistic processes that direct current and
future therapies
Chair:






tbc
Introduction
Alpha-1
Ageing
Imaging
Stem cells
Panel discussion
Rob Stockley (UK)
Gerry McElvaney (Ire)
Bill MacNee (UK)
David Parr (UK)
David Lomas (UK)
Preliminary programme COPD8
Clinical Science Mini Symposia
CS1. Vitamins and COPD
This session introduces the increasing evidence to implicate vitamins in the pathophysiology of
COPD
Chair:





Marc Decramer
Introduction: Why would vitamins be considered to be important
Rationale for use of Vitamin D in Chronic Disease
Vitamin D Deficiency in animal models
Vitamin D Status in COPD and effects of supplementation
Panel discussion
M Decramer (Bel)
Alice Wood (UK)
GR Zosky (Australia)
Wim Janssens (Bel)
CS2. Nature or nurture
This session will review the evidence that COPD is predetermined making the smoker susceptible
Chair:





tbc
Introduction: Why would COPD run in families
Early life influences
Is there a genetic predisposition that makes sense?
Lung development and population studies
Panel discussion
CS3. The roll of fat in COPD
This session explains how body habitas not only affects management but also influences the
pathophysiology of COPD
Chair:





Emil Wouters (NL)
Metabolic phenotype and adipose tissue inflammation in COPD
tbc
Influence on inflammation (20 min)
Guy Brusselle (Bel)
Influence on mechanics/physiology (20 min)
Denis O’Donnell (Can)
Implications for the management of COPD (20 min)
Emil Wouters (NL)
Panel discussion
CS4. Exacerbations
This session updates our knowledge of COPD exacerbations exploring the changes in incidence
and the understanding of the clinical effects and course
Chair:






Wisia Wedzicha & John Hurst
Introduction: Are exacerbations as important as they were? (10 min)
John Hurst (UK)
Epidemiology (20 min)
David Mannino (USA)
Are COPD exacerbations similar to asthma exacerbations (20 min)
Ian Pavord (UK)
Physiology changes (20 min)
Gavin Donaldson
Mechanisms of recovery (20 min)
Wisia Wedzicha (UK)
Panel discussion
Preliminary programme COPD8
Care Delivery Mini Symposia
CD1. Improving the management of the disease
This session will explore different aspects of supporting patients and clinicians to manage the
disease better
Chair: tbc

Introduction

Self management and supported self management

End of life care – can we do it better

Decision support aids – can they help the busy clinician?

Telehealth and monitoring – when is it useful and cost effective?
CD2. Rehabilitation and reablement
This session will provide an update on new developments in pulmonary rehabilitation and in other
aspects of the psychosocial care of patients
Chair:




Tim Griffiths Memorial Lecture
Sally Singh
Neurocognitive aspects – how do we include them?
Pulmonary rehabilitation after exacerbations – is there a clear case?
Reablement – what else is required?
CD3. Getting some of the basics right
This session will revisit some of the important interventions in preventing COPD and managing the
disease and its symptoms in the later stages
Chair: tbc

Smoking cessation making it happen

Oxygen assessments and review

Crisis breathlessness

Domiciliary NIV: When is it needed?
CD4. Achieving Quality outcomes in COPD
This session will describe key elements of a holistic approach to improving outcomes for people
living and working with COPD
Chair:





tbc
Introduction – ‘The outcomes based approach in England’
Effective preventative approaches
Understanding variation in care to deliver improvement
COPD and the impact on work: How can we keep people actively employed
Measuring patient experience